[go: up one dir, main page]

MX2009011384A - Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular. - Google Patents

Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.

Info

Publication number
MX2009011384A
MX2009011384A MX2009011384A MX2009011384A MX2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A
Authority
MX
Mexico
Prior art keywords
agonist
cellular immunity
adjuvant combinations
nkt activator
optional antigen
Prior art date
Application number
MX2009011384A
Other languages
English (en)
Inventor
Cory Ahonen
Randolph Noelle
Original Assignee
Immurx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immurx Inc filed Critical Immurx Inc
Publication of MX2009011384A publication Critical patent/MX2009011384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan combinaciones adyuvantes que comprenden por lo menos un activador de NKT, tal como alfa-galactosilceramida (a-Gal-Cer) o iGb3, un agonista de CD40 y opcionalmente un antígeno. También se proporciona el uso de estos adyuvantes inmunes para el tratamiento de varias enfermedades crónicas tales como cánceres.
MX2009011384A 2007-04-25 2008-04-25 Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular. MX2009011384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90797607P 2007-04-25 2007-04-25
PCT/US2008/005341 WO2008133983A1 (en) 2007-04-25 2008-04-25 Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity

Publications (1)

Publication Number Publication Date
MX2009011384A true MX2009011384A (es) 2010-03-18

Family

ID=39925993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011384A MX2009011384A (es) 2007-04-25 2008-04-25 Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.

Country Status (9)

Country Link
US (3) US8802098B2 (es)
EP (1) EP2150277B1 (es)
JP (1) JP5331100B2 (es)
KR (1) KR20100025514A (es)
CN (1) CN101730546B (es)
AU (1) AU2008246149B2 (es)
CA (1) CA2685125A1 (es)
MX (1) MX2009011384A (es)
WO (1) WO2008133983A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
WO2008133983A1 (en) * 2007-04-25 2008-11-06 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
CA3017298C (en) * 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
JP6456306B2 (ja) * 2013-02-20 2019-01-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ｉＮＫＴ細胞の活性化
JP6121597B1 (ja) * 2016-06-09 2017-04-26 株式会社スリービー 免疫応答活性化サイトカイン産生促進剤およびＴｈ１７細胞分化促進剤
CN113209302B (zh) * 2020-01-20 2022-11-18 成都医学院 一种具有抗肿瘤作用的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
CN1665533A (zh) * 2002-05-02 2005-09-07 康涅狄格大学健康中心 热激蛋白用于增强抗体疗法功效的用途
EP2572715A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7914792B2 (en) 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
RU2377254C2 (ru) * 2003-12-25 2009-12-27 Кирин Фарма Кабусики Кайся Мутанты анти-cd40 антитела
AU2005280163B2 (en) * 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DK1786439T3 (da) * 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
EP1833489A4 (en) * 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
CN101501055B (zh) 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
US7421888B2 (en) * 2005-12-12 2008-09-09 Southwest Research Institute Regenerative system for testing torque converters and other transmission coupling devices
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
WO2008133983A1 (en) * 2007-04-25 2008-11-06 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity

Also Published As

Publication number Publication date
AU2008246149B2 (en) 2013-09-12
US10463731B2 (en) 2019-11-05
EP2150277A4 (en) 2011-02-16
CA2685125A1 (en) 2008-11-06
AU2008246149A1 (en) 2008-11-06
EP2150277A1 (en) 2010-02-10
JP5331100B2 (ja) 2013-10-30
CN101730546B (zh) 2013-04-24
US20150004163A1 (en) 2015-01-01
US20160158348A1 (en) 2016-06-09
HK1140959A1 (en) 2010-10-29
US8802098B2 (en) 2014-08-12
KR20100025514A (ko) 2010-03-09
WO2008133983A1 (en) 2008-11-06
US20100247537A1 (en) 2010-09-30
US9238067B2 (en) 2016-01-19
CN101730546A (zh) 2010-06-09
EP2150277B1 (en) 2013-02-27
JP2010525065A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
MX2009011384A (es) Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
PH12019500518A1 (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PH12013501707A1 (en) Mesogen-containing compounds
DOP2015000098A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
MX2011007930A (es) Conjugados de insulina cristalina.
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
ECSP099724A (es) Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
GB0515353D0 (en) Food
CL2014000775A1 (es) Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras.
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
EP2162149A4 (en) VACCINE FOR PREVENTING A BREAST CANCER REVIVAL
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
EP2094293A4 (en) TISSUE ANTIGEN ACTIVATION OF THE IMMUNE RESPONSE FOR THE TREATMENT OF CANCER
IL207549A0 (en) Doxorubicin adjuvants to reduce toxicity and methods for using the same
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
UY31033A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal
CY1116914T1 (el) ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40
EP2035018A4 (en) PATHOGENIC DEHYDRATION THROUGH ADMINISTRATION OF EQUILIBIOTIC COMPOUND
AP2695A (en) Vaccine adjuvants
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
UA29848U (uk) Застосування системної реконструктивної терапії як способу лікування мігрені

Legal Events

Date Code Title Description
FG Grant or registration